Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clene Inc. - Common Stock (NQ:CLNN)

3.820 -0.050 (-1.29%)
Streaming Delayed Price Updated: 1:16 PM EDT, Jul 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clene Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Moves Lower; Micron Issues Strong Forecast
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded up 0.58% to 37,296.40 while the NASDAQ rose 0.77% to 14,891.87. The... 
Via Benzinga
Topics Stocks
Dow Jumps 250 Points; US Weekly Jobless Claims Edge Higher
U.S. stocks traded higher this morning, with the Dow Jones gaining around 250 points on Thursday. Following the market opening Thursday, the Dow traded up 0.72% to 37,348.90 while the NASDAQ rose 0.96%... 
Via Benzinga
Topics Stocks
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! 
Via InvestorPlace
Clene Inc. (NASDAQ: CLNN) Is ‘One to Watch’
Via Investor Brand Network
Expert Ratings for Clene
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
How Clene Inc. (NASDAQ: CLNN) CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Lead Drug Candidate Featured in Peer-Reviewed Publication Describing Brain Target Engagement in Neurodegenerative Diseases
Via Investor Brand Network
Stem Cell Therapy Shows Promise in Halting Progression of Cognitive Decline in MS Patients
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc.’s (NASDAQ: CLNN) Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patients
Via Investor Brand Network
The 2023 Nobel Prize in Chemistry’s Spotlight on Nanotechnology Shines Light on Clene Inc. (NASDAQ: CLNN) Efforts to Develop Catalytically Active Nanoparticles
Via Investor Brand Network
Study Suggests Parkinson’s Could Be Linked to Onset of Stroke, Heart Disease
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Capitalizing on the Promising Chemical and Therapeutic Properties of Nanocrystals to Address High Unmet Medical Needs
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Reports Q3 2023 Financial Results, Recent Operating Highlights for Its ALS Clinical Program
Via Investor Brand Network
Blood Test Could Detect Worsening MS Symptoms in Patients
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Among Grant Awardees Selected to Advance Scientific Research on ALS
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Q3 2023 Financial Results, Operating Highlights
Via Investor Brand Network
Australian Study Finds Way to Detect Parkinson’s Prior to Symptom Onset
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis; Announces Peer-Reviewed Study
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Clene Inc. (NASDAQ: CLNN) Announces Four-Year Grant to Support Expanded Access Protocol for CNM-Au8 From NINDS
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) ‘Innovates’ Investigational Drug with Patented Nanotechnology
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Applies Patented Nanotechnology to Development of CNM-Au8(R), its Investigational Drug for ALS
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Featured in Latest Episode of The Bell2Bell Podcast
Via Investor Brand Network
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces $45.1M NINDS Grant to Support Expanded Access Protocol for CNM-Au8(R) in ALS
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Investigational Drug Focus of Study Published in Peer-Reviewed Journal
Via Investor Brand Network
Clene's Neurogenerative Candidate Shows Potential For Improved Long-Term Survival
Clene Inc. (NASDAQ: CLNN) released long-term follow-up data for patients treated with CNM-Au8 30mg for up to 133 weeks in the  
Via Benzinga
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Releases Significant Long-Term Survival Improvement Data from ALS Trial
Via Investor Brand Network
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.